These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 25003616)

  • 61. [Beneficial effects of rituximab in the treatment of refractory nephrotic syndrome].
    Imai E
    Nihon Jinzo Gakkai Shi; 2012; 54(5):593-7. PubMed ID: 22991838
    [No Abstract]   [Full Text] [Related]  

  • 62. Rituximab in adult patients with immunosuppressive-dependent minimal change disease.
    Hoxha E; Stahl RA; Harendza S
    Clin Nephrol; 2011 Aug; 76(2):151-8. PubMed ID: 21762648
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Rituximab therapy in nephrotic syndrome: implications for patients' management.
    Sinha A; Bagga A
    Nat Rev Nephrol; 2013 Mar; 9(3):154-69. PubMed ID: 23338210
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Immunosuppressive therapies for refractory nephrotic syndrome].
    Mitarai T
    Nihon Jinzo Gakkai Shi; 2010; 52(7):924-7. PubMed ID: 21077342
    [No Abstract]   [Full Text] [Related]  

  • 65. Remission of steroid-resistant nephrotic syndrome due to focal and segmental glomerulosclerosis using rituximab.
    Suri M; Tran K; Sharma AP; Filler G; Grimmer J
    Int Urol Nephrol; 2008; 40(3):807-10. PubMed ID: 18491215
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Three-monthly bolus vitamin D supplements (1000 vs 400 IU/day) for prevention of bone loss in children with difficult-to-treat nephrotic syndrome: a randomised clinical trial.
    Singh DN; Krishnamurthy S; Kamalanathan SK; Harichandrakumar KT; Sivamurukan P
    Paediatr Int Child Health; 2018 Nov; 38(4):251-260. PubMed ID: 30092157
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Multicenter survey of diagnostic and therapeutic status in Chinese childhood patients with steroid-sensitive, relaping/steroid-dependent nephrotic syndrome].
    Working Group For National Survey On Status Of Diagnosis And Treatment Of Childhood Renal Diseases
    Zhonghua Er Ke Za Zhi; 2014 Mar; 52(3):194-200. PubMed ID: 24824389
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Does rituximab induce hypogammaglobulinemia in patients with pediatric idiopathic nephrotic syndrome?
    Delbe-Bertin L; Aoun B; Tudorache E; Lapillone H; Ulinski T
    Pediatr Nephrol; 2013 Mar; 28(3):447-51. PubMed ID: 23212560
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Risk factors for early relapse during maintenance therapy after a single infusion of rituximab in children with steroid-dependent nephrotic syndrome.
    Fujinaga S; Hirano D
    Pediatr Nephrol; 2014 Mar; 29(3):491-2. PubMed ID: 24240472
    [No Abstract]   [Full Text] [Related]  

  • 70. Rituximab followed by mycophenolate mofetil in children with IgM nephropathy.
    Gu J; Xia Y; Mao J; Fu H; Liu A
    Indian Pediatr; 2012 Oct; 49(10):831-3. PubMed ID: 23144102
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Rituximab for steroid-dependent nephrotic syndrome.
    Beco A; Castro-Ferreira I; Coentrao L; Neto R; Sampaio S; Pestana M
    Clin Nephrol; 2010 Oct; 74(4):308-10. PubMed ID: 20875384
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Controversial issues in the Giornale Italiano di Nefrologia: how to treat patients with focal segmental glomerular sclerosis].
    Passerini P; Scolari F; Frasca' GM; Leoni A; Venturelli C; Dallera N; Ravera S; Balestra E; Freddi P; Fanciulli E; D'Arezzo M; Sagripanti S
    G Ital Nefrol; 2009; 26(5):563-76. PubMed ID: 19802802
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Rituximab: is replacement of cyclophosphamide and calcineurin inhibitors in steroid-dependent nephrotic syndrome possible?
    Dötsch J; Müller-Wiefel DE; Kemper MJ
    Pediatr Nephrol; 2008 Jan; 23(1):3-7. PubMed ID: 17899207
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Unfavorable impact of anti-rituximab antibodies on clinical outcomes in children with complicated steroid-dependent nephrotic syndrome.
    Fujinaga S; Nishino T; Endo S; Umeda C; Watanabe Y; Nakagawa M
    Pediatr Nephrol; 2020 Oct; 35(10):2003-2008. PubMed ID: 32556955
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Critical evaluation of rituximab rescue in 27 patients with different types of kidney disease.
    Ganzemueller J; Hartmann B; Keller F; Stracke S
    Minerva Urol Nefrol; 2011 Dec; 63(4):263-72. PubMed ID: 21996981
    [TBL] [Abstract][Full Text] [Related]  

  • 76. New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome.
    van Husen M; Kemper MJ
    Pediatr Nephrol; 2011 Jun; 26(6):881-92. PubMed ID: 21229269
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Rituximab as a Therapeutic Option for Steroid-Sensitive Minimal Change Nephrotic Syndrome in Adults.
    Iwabuchi Y; Moriyama T; Itabashi M; Takei T; Nitta K
    Contrib Nephrol; 2018; 195():12-19. PubMed ID: 29734146
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Long-term effects of cyclophosphamide therapy in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome.
    Cammas B; Harambat J; Bertholet-Thomas A; Bouissou F; Morin D; Guigonis V; Bendeddouche S; Afroukh-Hacini N; Cochat P; Llanas B; Decramer S; Ranchin B
    Nephrol Dial Transplant; 2011 Jan; 26(1):178-84. PubMed ID: 20610527
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Efficacy and safety of rituximab treatment in children with primary glomerulonephritis.
    Zachwieja J; Silska M; Ostalska-Nowicka D; Soltysiak J; Lipkowska K; Blumczynski A; Musielak A
    J Nephrol; 2012; 25(6):1060-6. PubMed ID: 22322817
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Repeated course of rituximab for treatment of nephrotic syndrome in patients with chronic GVHD.
    Mellon-Reppen S; Ratanatharathorn V; Cronin S; Uberti JP
    Bone Marrow Transplant; 2010 Dec; 45(12):1758-9. PubMed ID: 20383208
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.